⁹⁹ᵐTc-Maraciclatide Demonstrates Potential to Differentiate Inflammation from Fibrosis in Interstitial Lung Disease

Phase 2 ^99mTc-maraciclatide data presented at SNMMI 2026 Annual Meeting show distinct αvβ3 integrin uptake in patients with ILD

Serac Healthcare Limited has presented Phase 2 data showing that SPECT-CT imaging with ^99mTc-maraciclatide has the potential to identify and differentiate active inflammation from fibrosis in patients with interstitial lung disease (ILD). The findings were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Los Angeles, USA, taking place from 30 May to 2 June and have been highlighted in an SNMMI press release: “New SPECT Imaging Approach Distinguishes Inflammation from Fibrosis to Optimize Treatment for Lung Disease.”